Monogram Announces Presentation Of Clinical Data For The HERmark TM Breast Cancer Assay At The 44th ASCO Annual Meeting

Monogram Biosciences, Inc.

Some Way To Go Before The Act Can 'Breathe Easy', Australian Medical Association

AMA ACT President, Dr Paul Jones, expressed concern that the ACT has been left behind on tobacco reform. The ACT has been placed well behind all States and only performed better than the Northern Territory on the 2008 Tobacco Scoreboard.

Nagging Headache Often Linked To Dental Pain

Could that nagging headache and painful jaw be tied to your oral health? Many headache sufferers might want to consult their dentist as well as their doctor since headaches and dental pain have a lot in common, says Director of the Orofacial Pain and Oral Medicine Graduate Program at the USC School of Dentistry Glenn Clark.

Solvent-Free Abraxane R Combined With Targeted Therapy Bevacizumab Evaluated As First-Line Treatment For Metastatic Breast Cancer

Abraxis BioScience, Inc.

Medivation Announces Presentation Of Positive MDV3100 Clinical Data In Castration-Resistant Prostate Cancer Patients At 44th ASCO Annual Meeting

Medivation, Inc. (Nasdaq: MDVN) announced that data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist, MDV3100, showed encouraging anti-tumor activity as measured by declining serum levels of prostate specific antigen (PSA) and circulating tumor cells (CTC), as well as radiographic disease stabilization, after three months of treatment.

Preventing Too Much Radioactive Exposure - Rabbit R Helps To Battle Cancer

"We looked at other processors, but having memory and I/O, and a dedicated C compiler with examples made Rabbit the right choice" - Martin Brown, Best Medical CanadaOne of the most effective methods to combat cancer and tumors is radiation therapy.

Erbitux - Enhanced Efficacy Demonstrated In Patients With KRAS Wild-Type Tumors In First Line Metastatic Colorectal Cancer

New analyses of two randomized, controlled clinical trials investigating Erbitux (cetuximab) in the treatment of 1st-line metastatic colorectal cancer (mCRC) highlight the increased efficacy of Erbitux in patients with "normal, " non-mutated or so-called tumors with wild-type KRAS.

Clinical Proof Of Concept For TGF-beta 2-Inhibitor AP 12009 In Phase IIb EMEA Provides Guidance On Phase III Design And Approval Requirements

"A two-year survival rate of more than 80 percent in recurrent or refractory anaplastic astrocytoma suggests a breakthrough in this devastating disease by targeted therapy, " commented Prof.

Bruker Daltonics Introduces MaXis trade;, A Revolutionary New Ultra-High Resolution TOF Mass Spectrometer

At ASMS 2008, Bruker Daltonics announced the maXis™ , a revolutionary new Electrospray Ultra-High Resolution tandem TOF (UHR-Qq-TOF) mass spectrometer.

Preliminary Analyses From Phase 2 Genzyme Study Highlight Efficacy And Safety Of Clofarabine In Older Adult AML Patients

Genzyme Corp. (Nasdaq: GENZ) reported preliminary data from a fully-enrolled pivotal, phase 2 study examining the safety and effectiveness of Clolar(R) (clofarabine) as a single agent in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from conventional "7+3" anthracycline plus cytarabine-based induction chemotherapy.